Article
Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.
Thyroid : official journal of the American Thyroid Association - 1 Sept 2020
Cabanillas Maria E, Dadu Ramona, Iyer Pryianka, Wanland Kacey B, Busaidy Naifa L, Ying Anita, Gule-Monroe Maria, Wang Jennifer R, Zafereo Mark, Hofmann Marie-Claude
Abstract excerpt
Background: The BRAFV600E mutation is the most common driver mutation in papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered actionable and, for BRAFV600E-mutated ATC, a BRAF inhibitor (dabrafenib) in combination with an MEK inhibitor (trametinib) is FDA approved. BRAF inhibitors have also shown efficacy in BRAFV600E-mutated PTC. However, as with all targeted therapies,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.